Effect of olmesartan medoxomilo on arterial stiffness in patients with essential hypertension;Efecto del olmesartán medoxomilo en la rigidez de las grandes arterias en pacientes con hipertensión arterial esencial

Medicina Clinica

Volumn 128, Issue 19, 2007, Pages 726-729

  García, Juan Diego Mediavilla ^a,b   Fernández Torres, Celia ^a   Águila, Fernando Jaén ^a   Jiménez Alonso, Juan ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b NONE   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Olmesartan medoxomil; Pulse wave velocity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; OLMESARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTERY LESION; ARTICLE; BLOOD PRESSURE MONITORING; CAROTID ARTERY; CORRELATION ANALYSIS; DEVICE; DISEASE SEVERITY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; FEMORAL ARTERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 34347343967     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13106127     Document Type: Article

References (34)

1. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111-7.
2. Laurent S, Boutouyrie P, Asmar R, Gauitier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-41.
3. Guérin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987-92.
4. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end stage renal falilure. Hypertension. 2001;38:434-8.
5. O'Rouke MF, Pauca A, Jiang XJ. Pulse wave analysis. Br J Clin Pharmacol. 2001;51:507-22.
6. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10-5.
7. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddey S, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41:1281-6.
8. Sattler KJE, Woodrum JE, Galili O, Olson M, Samee S, Meyer FB, et al. Concurrent treatment with renin-angiotensin system blockers and acetylsaliciylic acid reduces nuclear factor B activation an C-reactive protein expression in human carotid artery plaques. Stroke. 2005;36:14-20.
9. Safar M, Van Bortel L, Struijker-Boudier H. Resistance and conduit arteries following converting-enzyme inhibition in hypertension. J Vascular Res. 1997;81:34-67.
10. Lacourciére Y, Béliveau R, Conter IIS, Burgess ED, Lepage S, Pesant Y, et al. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. Can J Cardiol. 2004;20:795-9.
11. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905-10.
12. Yang H, Deng Y, Li C, Bi X, Pan M, Chang Q. Assessment of effect of angiotensin II receptor antagonist losartan on aortic distensibility in patients with essential hypertension by echography. J Huazhong Univ Sci Technolog Med Sci. 2002;22:164-7.
13. Guidelines Committee. 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
14. Staessen J, Fagard R, Lijnen P, Thijs L, Van Hoof R, Amery A. Reference values for ambulatory blood pressure: a metaanalysis. J Hypertens. 1990;8 Suppl 6:57-64.
15. Shennan AH, Halligan AW. Korotkoff sounds. Blood Press Monit. 1996;1:495.
16. Groppelli A, Omboni S, Ravogli A, Villani A, Parati G, Mancia GI. Validation of the Spacelabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens. 1991;9 Suppl 3:334-55.
17. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995;26:485-90.
18. rd ed. London: Edward Arnold; 1990. p. 77-142, 216-69, 283-359, 308-437.
19. Pannier BM, Avolio AP, Hoeks A, Mancia G, Takazawa K. Methods and devices for measuring arterial compliance in humans. Am J Hypertens. 2002;15:743-53.
20. Asmar R, Benetos A, London G, Hugue Ch, Weiss Y, Topouchian J, et al. Aortic distensibility in normotensive untreated and treated hypertensive patients. Blood Press. 1995;4:48-54.
21. O'Rourke M. Mechanical principles in arterial disease. Hypertension. 1995;26:2-9.
22. Asmar R, Rudnicki A, Blacher J, London GM, Safar ME. Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens. 2001;14:91-7.
23. Asmar R. Arterial stiffness and pulse wave velocity, clinical applications. Amsterdam: Elservier; 2000. p. 9-15.
24. Asmar J, Ruidavets JB, Chamontin B, Drouet L, Ferrieres J. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens. 2001;19:381-7.
25. Rehman A, Rahman ARA, Rasool AHG. Effect of angiotesin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT1) receptors. J Human Hypertension. 2002;16:261-6.
26. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Human Hypertension. 2006;20:787-94.
27. Asmar R. Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus. J Renin Angiotensin Aldosterone Syst. 2001;2:S8-S11.
28. Nürnberger J, Dammer S, Opazo Sáez A, Philipp T, Schäfers RF. Diastolic blood pressure is an important determinant of augmentation index and pulse wave velocity in young, healthy males. J Human Hypertens. 2003;17:153-8.
29. Benetos A, Waeber B, Izzo JL, Mitchell G, Resnick K, Asmar R, et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens. 2002;15:1101-8.
30. Khoshdel AR, Thkkinstian A, Carney SL, Attia J. Estimation of an age-specific reference interval for pulse wave velocity: a meta-analysis. J Hypertens. 2006;24:1231-7.
31. Rajzer MW, Klocek M, Kawecka-Jaszcz K, Czarnecka D, Baran W, Dudek K, et al. Aortic pulse wave velocity in young normotensives with a family history of hypertension. J Hypertens. 1999;17:1821-4.
32. Neutel JM, Elliot WJ, Izzo JL, Chen C, Masonson HN. Antihypetensive efficacy of olmesartan medoxomil, a new angiotesin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens. 2002;4:325-31.
33. Destro M, Scabrosetti R, Vanasia A, Mugellini A. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24 hour ambulatory blood pressure monitoring. Advances in Therapy. 2005;22:32-43.
34. Smith DHG, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy. A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:41-50.